LENZ Therapeutics (NASDAQ:LENZ) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note issued to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $38.00 price target on the stock. HC Wainwright also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.50) EPS, Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.72) EPS, FY2024 earnings at ($2.59) EPS, FY2025 earnings at ($3.07) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at $0.46 EPS.

Several other brokerages have also weighed in on LENZ. Leerink Partnrs reissued an outperform rating on shares of LENZ Therapeutics in a report on Monday, April 15th. William Blair assumed coverage on LENZ Therapeutics in a research note on Monday, April 15th. They set an outperform rating on the stock. Finally, SVB Leerink initiated coverage on shares of LENZ Therapeutics in a report on Monday, April 15th. They issued an outperform rating and a $32.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and an average target price of $33.00.

LENZ Therapeutics Stock Up 1.4 %

Shares of LENZ stock opened at $23.50 on Monday. The business’s fifty day moving average is $20.44. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $29.82.

Institutional Trading of LENZ Therapeutics

A number of large investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new stake in shares of LENZ Therapeutics in the first quarter valued at approximately $830,000. Jennison Associates LLC acquired a new position in shares of LENZ Therapeutics during the first quarter valued at $3,009,000. Ikarian Capital LLC acquired a new stake in LENZ Therapeutics in the first quarter worth about $1,898,000. American International Group Inc. bought a new position in LENZ Therapeutics in the 1st quarter valued at about $44,000. Finally, BNP Paribas Financial Markets bought a new position in LENZ Therapeutics in the 1st quarter valued at about $362,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.